摘要
目的探讨重组人血小板生成素联合地塞米松疗法对免疫性血小板减少症患者血浆T淋巴细胞亚群的影响。方法选取2013年3月~2016年1月在我院进行治疗的免疫性血小板减少症患者共236例,分为研究组和对照组,每组各116例,其中对照组采用单纯地塞米松进行治疗,研究组采用重组人血小板生成素联合地塞米松治疗;对比两组患者治疗前后的血小板变化情况及治疗效果进行分析,使用流式细胞分析对两组患者治疗前后血浆T淋巴细胞亚群的变化情况进行分析,对血浆T淋巴细胞亚群在此类疾病患者治疗及预后中可能发挥的作用进行探讨。结果两组患者治疗前血小板数量无显著差异(P=0.2607),治疗后血小板均有大幅上升,与治疗前有显著差异,但研究组患者的血小板数量明显高于对照组(P<0.01);研究组患者的总有效率明显高于对照组,且组间差异具有统计学意义(P=0.0005);治疗前后对照组患者除T淋巴细胞数量外其余细胞亚群占比均无显著变化,而研究组患者各项统计参数均有显著变化,除CD^(8+)亚群占比外其余统计数据均明显高于对照组。结论重组人血小板生成素联合地塞米松疗法对免疫性血小板减少具有较好的临床疗效,且能够有效提高患者T淋巴细胞亚群的数量,理论上能够有效的从根源上治疗此类疾病,抑制患者的复发情况。
Objective To investigate the effect of recombinant human thrombopoietin in combination with dexamethasone therapy to reduce the impact of subsets of patients with plasma T lymphocytes in immune thrombocytopenic. Methods From March 2013-2016 years in January for immune thrombocytopenic treatment in our hospital reduced in patients with a total of 236 cases, divided into study group and control group, 116 cases in each group, the control group treated with dexamethasone treatment, study group was treated with recombinant human thrombopoietin in combination with dexamethasone; analysis of platelet changes and the treatment effect before and after comparison two groups of patients,the use of flow cytometry analysis of changes of plasma T lymphocyte subsets before and after treatment in two groups of patients were analyzed to investigate the plasma levels of T lymphocyte subsets in the treatment and prognosis of patients with this disease may play a role in. Results Two groups of patients before treatment, no significant difference in platelet count（P = 0. 2607） ,after treatment significantly increased,there were significant differences before and after treatment, but the number of platelets in patients of the study group was significantly higher than the control group（ P 〈 0. 01 ） ;patients in the study group, the total effective rate was significantly higher than the control group,the difference was statistically significant and group between before and after treatment （P = 0. 0005）;patients in the control group except the T lymphocyte cell subsets proportion had no significantchange, while the study group of patients with various statistical parameters have significant changes, in addition to subgroup CD8 ＋ accounted for the statistical data were significantly higher than the control group. Conclusion Recombinant human thrombopoietin combined with dexamethasone therapy has good clinical curative effect on immune thrombocytopenia, and can effectively increase the number of T lymphocyte subsets in patients with, theory can effectively treat this disease from the root, inhibit the recurrence in patients with the situation, it is worthy of clinical promotion.
出处
《血栓与止血学》
2017年第4期541-544,共4页
Chinese Journal of Thrombosis and Hemostasis
